For older people and frail people, the long-term benefit of medicines reduces and the potential for harm from adverse effects increases. When the benefit–risk balance changes in this way, medicine review and optimisation are important to simplify the therapeutic regimen, reduce inappropriate medicines and minimise risks. In this article, pharmacist prescriber Linda Bryant uses two case studies to illustrate important considerations during medicine reviews
Retirement from the RCPA - Dr Debra Graves OAM (CEO)
Retirement from the RCPA - Dr Debra Graves OAM (CEO)

Dr Debra Graves OAM, Chief Executive Officer (CEO) of the Royal College of Pathologists of Australasia (RCPA), has advised the RCPA Board of her decision to retire after almost 25 years as CEO. March 28th will be her last day of work (subject to the successful appointment of her successor).
RCPA President, Dr Lawrie Bott said:
‘On behalf of the RCPA Board, I have regrettably accepted Debra’s decision to retire, however we understand her desire to enter this new phase of her life after more than two decades in the role.
On behalf of the College, let me clearly state how much we value Debra’s contribution over so many years. We congratulate her on a wonderful career that has certainly improved the provision of Pathology in all the countries that the College covers. She has demonstrated strong leadership and personal dedication to the benefit of Fellows, Trainees, Colleagues, Patients and the Community, and I sincerely thank Debra for her tremendous contribution throughout her tenure.’
Executive search activity is underway, but it remains business very much as usual at the RCPA. Dr Graves will be leading the College until her last day in the office and this includes working closely with her successor to ensure a smooth transition for the College and its Fellows and Trainees throughout Australasia.